Sutro Biopharma Stock Market Value
| STRO Stock | USD 18.42 1.14 5.83% |
| Symbol | Sutro |
Will Biotechnology sector continue expanding? Could Sutro diversify its offerings? Factors like these will boost the valuation of Sutro Biopharma. If investors know Sutro will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Sutro Biopharma data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (2.60) | Revenue Per Share | Quarterly Revenue Growth 0.138 | Return On Assets | Return On Equity |
Understanding Sutro Biopharma requires distinguishing between market price and book value, where the latter reflects Sutro's accounting equity. The concept of intrinsic value - what Sutro Biopharma's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Sutro Biopharma's price substantially above or below its fundamental value.
Please note, there is a significant difference between Sutro Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sutro Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Sutro Biopharma's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Sutro Biopharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Sutro Biopharma's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Sutro Biopharma.
| 11/24/2025 |
| 02/22/2026 |
If you would invest 0.00 in Sutro Biopharma on November 24, 2025 and sell it all today you would earn a total of 0.00 from holding Sutro Biopharma or generate 0.0% return on investment in Sutro Biopharma over 90 days. Sutro Biopharma is related to or competes with Artiva Biotherapeutics, Precision BioSciences, Pliant Therapeutics, Fractyl Health, InflaRx NV, Metagenomi Common, and Connect Biopharma. Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company More
Sutro Biopharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Sutro Biopharma's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Sutro Biopharma upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 5.91 | |||
| Information Ratio | 0.1892 | |||
| Maximum Drawdown | 29.1 | |||
| Value At Risk | (7.78) | |||
| Potential Upside | 11.87 |
Sutro Biopharma Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Sutro Biopharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Sutro Biopharma's standard deviation. In reality, there are many statistical measures that can use Sutro Biopharma historical prices to predict the future Sutro Biopharma's volatility.| Risk Adjusted Performance | 0.1628 | |||
| Jensen Alpha | 1.13 | |||
| Total Risk Alpha | 0.6806 | |||
| Sortino Ratio | 0.202 | |||
| Treynor Ratio | 0.6492 |
Sutro Biopharma February 22, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1628 | |||
| Market Risk Adjusted Performance | 0.6592 | |||
| Mean Deviation | 4.86 | |||
| Semi Deviation | 4.84 | |||
| Downside Deviation | 5.91 | |||
| Coefficient Of Variation | 495.07 | |||
| Standard Deviation | 6.31 | |||
| Variance | 39.77 | |||
| Information Ratio | 0.1892 | |||
| Jensen Alpha | 1.13 | |||
| Total Risk Alpha | 0.6806 | |||
| Sortino Ratio | 0.202 | |||
| Treynor Ratio | 0.6492 | |||
| Maximum Drawdown | 29.1 | |||
| Value At Risk | (7.78) | |||
| Potential Upside | 11.87 | |||
| Downside Variance | 34.91 | |||
| Semi Variance | 23.41 | |||
| Expected Short fall | (5.35) | |||
| Skewness | 0.4055 | |||
| Kurtosis | 0.7334 |
Sutro Biopharma Backtested Returns
Sutro Biopharma is unstable given 3 months investment horizon. Sutro Biopharma owns Efficiency Ratio (i.e., Sharpe Ratio) of 0.22, which indicates the firm had a 0.22 % return per unit of risk over the last 3 months. We were able to interpolate data for thirty different technical indicators, which can help you to evaluate if expected returns of 1.42% are justified by taking the suggested risk. Use Sutro Biopharma Semi Deviation of 4.84, risk adjusted performance of 0.1628, and Coefficient Of Variation of 495.07 to evaluate company specific risk that cannot be diversified away. Sutro Biopharma holds a performance score of 17 on a scale of zero to a hundred. The entity has a beta of 1.95, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Sutro Biopharma will likely underperform. Use Sutro Biopharma semi variance, as well as the relationship between the rate of daily change and relative strength index , to analyze future returns on Sutro Biopharma.
Auto-correlation | 0.65 |
Good predictability
Sutro Biopharma has good predictability. Overlapping area represents the amount of predictability between Sutro Biopharma time series from 24th of November 2025 to 8th of January 2026 and 8th of January 2026 to 22nd of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Sutro Biopharma price movement. The serial correlation of 0.65 indicates that roughly 65.0% of current Sutro Biopharma price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.65 | |
| Spearman Rank Test | 0.58 | |
| Residual Average | 0.0 | |
| Price Variance | 4.0 |
Pair Trading with Sutro Biopharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Sutro Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sutro Biopharma will appreciate offsetting losses from the drop in the long position's value.Moving together with Sutro Stock
| 0.82 | GXEA | Galapagos NV Earnings Call Tomorrow | PairCorr |
| 0.78 | 8VP1 | AVRICORE HEALTH INC | PairCorr |
| 0.73 | EQ | Equillium | PairCorr |
Moving against Sutro Stock
| 0.76 | OSE | OSE Pharma SA | PairCorr |
| 0.72 | VCYT | Veracyte Earnings Call This Week | PairCorr |
| 0.71 | RAC | Race Oncology Earnings Call Tomorrow | PairCorr |
| 0.67 | DRMA | Dermata Therapeutics | PairCorr |
| 0.35 | VCEL | Vericel Corp Ord Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to Sutro Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Sutro Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Sutro Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Sutro Biopharma to buy it.
The correlation of Sutro Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Sutro Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Sutro Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Sutro Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Sutro Biopharma Correlation, Sutro Biopharma Volatility and Sutro Biopharma Performance module to complement your research on Sutro Biopharma. To learn how to invest in Sutro Stock, please use our How to Invest in Sutro Biopharma guide.You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Sutro Biopharma technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.